Barbara Weber (LinkedIn)
April 9, 2020 08:00 AM EDT
Financing
R&D

Tan­go Ther­a­peu­tics nabs $60M in CRISPR-based hunt for hid­den can­cer genes

Jason Mast

Editor

Like a few oth­er CEOs, Bar­bara We­ber emerged from the JP Mor­gan Health­care Con­fer­ence up­beat. She had been test­ing the wa­ters of a Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times